Vancomycin ready to use - Xellia Pharmaceuticals

Drug Profile

Vancomycin ready to use - Xellia Pharmaceuticals

Alternative Names: Premixed Vancomycin RTU; Vancomycin Ready-to-Use (RTU) Bag; Vancomycin Ready-to-Use (RTU) Bag - Xellia Pharmaceuticals; Vancomycin-RTU bag

Latest Information Update: 28 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Xellia Pharmaceuticals
  • Class Antibacterials; Glycopeptides; Peptide antibiotics
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Bacterial infections

Most Recent Events

  • 21 Mar 2018 Clinical trials in Infections in Norway (IV)
  • 21 Mar 2018 Vancomycin ready to use bag - Xellia Pharmaceuticals receives Qualified Infectious Disease Product status from US FDA for Bacterial infections in USA
  • 21 Mar 2018 Xellia Pharmaceuticals announces intention to submit NDA for Vancomycin ready to use bag to US FDA in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top